查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1933327

全球心房颤动市场：市场规模、占有率、成长率、产业分析、依类型、应用和地区划分的分析及预测（2026-2034 年）

Atrial Fibrillation Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
出版日期: | 出版商: Fortune Business Insights Pvt. Ltd. | 英文 143 Pages | 商品交期: 请询问到货日

价格

心房颤动市场成长因素

受心血管疾病盛行率上升、人口老化以及药物治疗不断进步的推动，全球心房颤动市场正经历稳定成长。心房颤动（Afib）是一种以不规则、通常快速的心律为特征的心律不整，会显着增加中风、心臟衰竭和其他心血管併发症的风险。此疾病与高血压、心肌病变、肥胖、吸烟和老化密切相关，使其成为全球日益严重的公共卫生问题。

2025年全球心房颤动市场价值为172.4亿美元。预计到2026年，该市场将成长至179.9亿美元，到2034年将达到257.5亿美元，2026年至2034年的复合年增长率为4.59%。市场的持续扩张反映了对有效长期治疗方案的需求不断增长，以及患者获得治疗选择的机会日益增加。

市场驱动因素

心血管疾病负担日益加重是推动市场成长的关键因素之一。根据世界卫生组织（WHO）统计，到2023年，全球将有12.8亿成年人患有高血压，而高血压是心房颤动的主要危险因子。高血压引起的心臟结构和功能改变会显着增加心律不整的发生率。

此外，老年人口的快速成长也导致心房颤动盛行率上升。根据联合国2023年的报告，预计到2050年，65岁及以上人口将达到16亿，这将导致对心房颤动治疗的需求增加。发展中地区人们对心房颤动的认识提高、早期诊断和医疗保健服务的普及也促进了市场成长。

市场趋势

影响市场的关键趋势是，人们越来越关注新药研发，特别是单株抗体和因子XI/因子XIa抑制剂。大型製药公司正在大力投资创新疗法，以降低出血风险并维持抗凝血疗效。例如，Anthos Therapeutics公司正在开发avelaccimab，这是一种全人源单株抗体，可在不损害止血功能的情况下提供抗凝血作用。

监管机构也正在透过授予快速审批通道和特殊认定来支持创新，加速新型疗法的临床开发和市场准入。预计这一趋势将在预测期内显着改善治疗效果并扩大治疗选择。

新冠疫情的影响

在新冠疫情期间，心房颤动市场成长放缓，主要原因是供应链中断、诊所暂时关闭、择期手术减少。根据2022年发表在 "临床医学杂誌" 上的一篇论文，导管消融术和左心耳封堵术在疫情期间显着减少。

然而，药物治疗仍然是首选的治疗方法，支撑了稳定的药物需求。随着疫情后的復苏，诊断数量和治疗启动数量均恢復，市场也恢復正常的成长水准。

限制因子

儘管成长前景光明，市场仍面临诸多挑战，包括产品召回事件增多以及替代疗法的出现。因生产缺陷、标籤错误和品质问题导致的产品召回可能会对品牌信任度和患者依从性产生负面影响。例如，2023年多非利特和地高辛的回想引发了安全担忧，暂时削弱了市场信心，并可能导致患者转向非药物疗法。

细分市场分析

依药物类别划分，市场分为抗凝血剂和抗心律不整药物。抗凝血剂市场在强有力的临床指南和直接口服抗凝血剂 (DOAC) 的广泛应用推动下，预计将在 2026 年占 78.92% 的市场占有率。

依给药途径划分，口服给药途径预计将在 2026 年占 84.98% 的市场占有率。这主要得益于口服给药的便捷性、更高的患者依从性以及多种口服药物的选择。

依分销管道划分，零售药局预计在 2026 年占 48.03% 的市场占有率。这主要得益于零售药局的便利性、不断扩大的药局网路以及成本优势。

区域洞察

北美地区预计将在 2025 年引领心房颤动市场，占 38.33% 的市占率（价值 66.1 亿美元）。该地区的优势包括高疾病发生率、强有力的监管支持和人口老化。预计到2026年，美国市场规模将达到61.4亿美元。

欧洲占第二大市场占有率，这主要得益于心血管疾病发生率的上升和强劲的研发投入。亚太地区预计将实现最快成长，这得益于公众意识的提高、医疗基础设施的扩展以及人口的快速老化。预计到2026年，日本、中国和印度的市场规模将分别达到6.9亿美元、8.9亿美元和6.4亿美元。

目录

第一章：引言

第二章：摘要整理

第三章：市场动态

  • 市场驱动因素
  • 市场限制因素
  • 市场机遇
  • 市场趋势

第四章：关键考虑因素

  • 主要地区心律不整盛行率/发生率（2024/2025）
  • 主要产业趋势：併购、业务合作
  • 主要公司新产品发布
  • COVID-19 对心房颤动市场的影响

第五章：全球心房颤动市场分析：洞察与预测（2021-2034）

  • 市场分析、洞察与预测：依药物类别划分
    • 抗凝血药
    • 抗心律不整药
  • 市场分析、洞察与预测：依给药途径划分
    • 口服
    • 静脉注射
    • 其他
  • 市场分析、洞察与预测：依通路划分
    • 医院药房
    • 线上药房
    • 零售药房
  • 市场分析、洞察与预测：依地区划分
    • 北美
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲

章节第六章 北美心房颤动市场分析、洞察与预测（2021-2034）

  • 依国家划分
    • 美国
    • 加拿大

第七章：欧洲心房颤动市场分析、洞察与预测（2021-2034）

  • 依国家划分
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 斯堪的纳维亚
    • 欧洲其他地区

第八章 亚太地区心房颤动市场分析、洞察与预测（2021-2034）

  • 依国家/地区划分
    • 日本
    • 中国
    • 印度
    • 澳大利亚
    • 东南亚
    • 亚太其他地区

第九章：拉丁美洲心房颤动市场分析、洞察与预测（2021-2034）

  • 依国家划分
    • 巴西
    • 墨西哥
    • 拉丁美洲其他地区

第十章：中东与非洲心房颤动市场分析、洞察与预测（2021-2034）

  • 依国家划分
    • 海湾合作委员会（GCC）国家
    • 南非
    • 其他中东国家东非/非洲

第11章 竞争分析

  • 全球市场占有率分析(2025年)
  • 企业简介
    • Bristol-Myers Squibb Company
    • Sanofi
    • Eisai Co., Ltd.
    • Johnson &Johnson
    • Daiichi Sankyo, Inc.
    • Par Pharmaceutical
    • Bayer AG
    • Pfizer Inc.
Product Code: FBI108921

Growth Factors of atrial fibrillation Market

The global atrial fibrillation market is experiencing steady growth, driven by the rising prevalence of cardiovascular disorders, increasing geriatric population, and continuous advancements in pharmacological therapies. Atrial fibrillation (Afib) is a cardiac arrhythmia characterized by irregular and often rapid heart rhythm, which significantly increases the risk of stroke, heart failure, and other cardiovascular complications. The condition is commonly associated with hypertension, cardiomyopathy, obesity, smoking, and advancing age, making it a growing public health concern worldwide.

In 2025, the global atrial fibrillation market size was valued at USD 17.24 billion. The market is projected to grow to USD 17.99 billion in 2026 and further reach USD 25.75 billion by 2034, exhibiting a CAGR of 4.59% from 2026 to 2034. The consistent expansion of the market reflects the increasing demand for effective long-term management therapies and improved patient access to treatment options.

Market Drivers

The rising burden of cardiovascular diseases is one of the primary factors driving market growth. According to the World Health Organization (WHO), 1.28 billion adults globally were suffering from hypertension in 2023, a key risk factor for atrial fibrillation. Structural and functional changes in the heart caused by hypertension significantly increase the likelihood of arrhythmias.

Additionally, the rapidly growing geriatric population is contributing to the rising prevalence of Afib. As per the United Nations 2023 report, the global population aged 65 years and above is projected to reach 1.6 billion by 2050, leading to higher demand for atrial fibrillation therapies. Increasing awareness, early diagnosis, and expanding access to healthcare services in developing regions are further supporting market growth.

Market Trends

A major trend shaping the market is the increasing focus on novel drug development, particularly monoclonal antibodies and Factor XI/XIa inhibitors. Key pharmaceutical players are investing heavily in innovative therapies aimed at reducing bleeding risks while maintaining anticoagulant efficacy. For instance, Anthos Therapeutics is developing abelacimab, a fully human monoclonal antibody designed to provide hemostasis-sparing anticoagulation.

Regulatory bodies are also supporting innovation by granting fast-track approvals and special designations, enabling faster clinical development and market entry of novel therapies. This trend is expected to significantly improve treatment outcomes and expand therapeutic options during the forecast period.

COVID-19 Impact

The atrial fibrillation market experienced slow growth during the COVID-19 pandemic, mainly due to supply chain disruptions, temporary clinic closures, and reduced elective procedures. According to a 2022 publication in the Journal of Clinical Medicine, there was a notable decline in catheter ablation and left atrial appendage occlusion procedures during the pandemic.

However, pharmacotherapy remained the preferred treatment approach, supporting steady drug demand. Post-pandemic recovery led to a rebound in diagnoses and treatment initiation, allowing the market to return to normal growth levels.

Restraining Factors

Despite positive growth prospects, the market faces challenges from rising product recalls and the availability of alternative treatment approaches. Product recalls due to manufacturing defects, labeling errors, and quality concerns can negatively impact brand trust and patient adherence. For example, recalls of drugs such as dofetilide and digoxin in 2023 raised safety concerns and temporarily affected market confidence, potentially shifting patient preference toward non-pharmacological interventions.

Segmentation Analysis

By drug class, the market is segmented into anticoagulants and antiarrhythmic drugs. The anticoagulants segment dominated the market, accounting for 78.92% share in 2026, driven by strong clinical guidelines and widespread adoption of direct oral anticoagulants (DOACs).

By route of administration, the oral segment led the market with an 84.98% share in 2026, owing to ease of use, better patient compliance, and a wide range of orally available drugs.

By distribution channel, retail pharmacies dominated with a 48.03% share in 2026, supported by consumer convenience, expanding pharmacy networks, and cost advantages.

Regional Insights

North America dominated the atrial fibrillation market in 2025, accounting for 38.33% market share and valued at USD 6.61 billion. The region benefits from a high disease prevalence, strong regulatory support, and a large elderly population. The U.S. market is projected to reach USD 6.14 billion by 2026.

Europe held the second-largest share, driven by increasing cardiovascular disease prevalence and strong R&D investments. Asia Pacific is projected to witness the fastest growth due to rising awareness, expanding healthcare infrastructure, and a rapidly aging population. By 2026, Japan, China, and India are projected to reach USD 0.69 billion, USD 0.89 billion, and USD 0.64 billion, respectively.

Competitive Landscape

The global market is semi-consolidated, with key players such as Bayer AG, Bristol-Myers Squibb, Daiichi Sankyo, Sanofi, Pfizer, and Johnson & Johnson. These companies focus on product innovation, clinical trials, geographic expansion, and strategic collaborations to strengthen their market positions.

Conclusion

The global atrial fibrillation market is poised for steady growth, supported by the rising prevalence of cardiovascular disorders, an expanding geriatric population, and continuous advancements in drug development. Valued at USD 17.24 billion in 2025, the market is expected to grow to USD 25.75 billion by 2034. While challenges such as product recalls and alternative treatment options persist, ongoing innovation, supportive regulatory frameworks, and increasing global awareness are expected to sustain market expansion and create long-term growth opportunities.

Segmentation By Drug Class

  • Anticoagulants
  • Antiarrhythmic Drugs

By Route of Administration

  • Oral
  • Intravenous
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Online Pharmacies
  • Retail Pharmacies

By Region

  • North America (By Drug Class, Route of Administration, Distribution Channel, and Country)
    • U.S.
    • Canada
  • Europe (By Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
    • U.K.
    • Germany
    • France
    • Spain
    • Italy
    • Scandinavia
    • Rest of Europe
  • Asia Pacific (By Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
    • China
    • India
    • Japan
    • Australia
    • Southeast Asia
    • Rest of Asia Pacific
  • Latin America (By Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East & Africa (By Drug Class, Route of Administration, Distribution Channel, and Country/Sub-region)
    • GCC
    • South Africa
    • Rest of the Middle East & Africa

Table of Content

1. Introduction

  • 1.1. Research Scope
  • 1.2. Market Segmentation
  • 1.3. Research Methodology

2. Executive Summary

3. Market Dynamics

  • 3.1. Market Drivers
  • 3.2. Market Restraints
  • 3.3. Market Opportunities
  • 3.4. Market Trends

4. Key Insights

  • 4.1. Prevalence/Incidence of Arrhythmia, Key Region, 2024/2025
  • 4.2. Key Industry Developments - Mergers, Partnerships, Acquisitions
  • 4.3. New Product Launches by Key Players
  • 4.4. Impact of COVID-19 on Atrial Fibrillation Market

5. Global Atrial Fibrillation Market Analysis, Insights and Forecast, 2021-2034

  • 5.1. Market Analysis, Insights and Forecast - By Drug Class
    • 5.1.1. Anticoagulants
    • 5.1.2. Anti-arrhythmic Drugs
  • 5.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 5.2.1. Oral
    • 5.2.2. Intravenous
    • 5.2.3. Others
  • 5.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 5.3.1. Hospital Pharmacies
    • 5.3.2. Online Pharmacies
    • 5.3.3. Retail Pharmacies
  • 5.4. Market Analysis, Insights and Forecast - By Region
    • 5.4.1. North America
    • 5.4.2. Europe
    • 5.4.3. Asia Pacific
    • 5.4.4. Latin America
    • 5.4.5. Middle East & Africa

6. North America Atrial Fibrillation Market Analysis, Insights and Forecast, 2021-2034

  • 6.1. Market Analysis, Insights and Forecast - By Drug Class
    • 6.1.1. Anticoagulants
    • 6.1.2. Anti-arrhythmic Drugs
  • 6.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 6.2.1. Oral
    • 6.2.2. Intravenous
    • 6.2.3. Others
  • 6.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 6.3.1. Hospital Pharmacies
    • 6.3.2. Online Pharmacies
    • 6.3.3. Retail Pharmacies
  • 6.4. Market Analysis, Insights and Forecast - By Country
    • 6.4.1. U.S.
      • 6.4.1.1. By Drug Class
    • 6.4.2. Canada
      • 6.4.2.1. By Drug Class

7. Europe Atrial Fibrillation Market Analysis, Insights and Forecast, 2021-2034

  • 7.1. Market Analysis, Insights and Forecast - By Drug Class
    • 7.1.1. Anticoagulants
    • 7.1.2. Anti-arrhythmic Drugs
  • 7.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 7.2.1. Oral
    • 7.2.2. Intravenous
    • 7.2.3. Others
  • 7.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 7.3.1. Hospital Pharmacies
    • 7.3.2. Online Pharmacies
    • 7.3.3. Retail Pharmacies
  • 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 7.4.1. Germany
      • 7.4.1.1. By Drug Class
    • 7.4.2. U.K.
      • 7.4.2.1. By Drug Class
    • 7.4.3. France
      • 7.4.3.1. By Drug Class
    • 7.4.4. Spain
      • 7.4.4.1. By Drug Class
    • 7.4.5. Italy
      • 7.4.5.1. By Drug Class
    • 7.4.6. Scandinavia
      • 7.4.6.1. By Drug Class
    • 7.4.7. Rest of Europe
      • 7.4.7.1. By Drug Class

8. Asia Pacific Atrial Fibrillation Market Analysis, Insights and Forecast, 2021-2034

  • 8.1. Market Analysis, Insights and Forecast - By Drug Class
    • 8.1.1. Anticoagulants
    • 8.1.2. Anti-arrhythmic Drugs
  • 8.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 8.2.1. Oral
    • 8.2.2. Intravenous
    • 8.2.3. Others
  • 8.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 8.3.1. Hospital Pharmacies
    • 8.3.2. Online Pharmacies
    • 8.3.3. Retail Pharmacies
  • 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 8.4.1. Japan
      • 8.4.1.1. By Drug Class
    • 8.4.2. China
      • 8.4.2.1. By Drug Class
    • 8.4.3. India
      • 8.4.3.1. By Drug Class
    • 8.4.4. Australia
      • 8.4.4.1. By Drug Class
    • 8.4.5. Southeast Asia
      • 8.4.5.1. By Drug Class
    • 8.4.6. Rest of Asia Pacific
      • 8.4.6.1. By Drug Class

9. Latin America Atrial Fibrillation Market Analysis, Insights and Forecast, 2021-2034

  • 9.1. Market Analysis, Insights and Forecast - By Drug Class
    • 9.1.1. Anticoagulants
    • 9.1.2. Anti-arrhythmic Drugs
  • 9.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 9.2.1. Oral
    • 9.2.2. Intravenous
    • 9.2.3. Others
  • 9.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 9.3.1. Hospital Pharmacies
    • 9.3.2. Online Pharmacies
    • 9.3.3. Retail Pharmacies
  • 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 9.4.1. Brazil
      • 9.4.1.1. By Drug Class
    • 9.4.2. Mexico
      • 9.4.2.1. By Drug Class
    • 9.4.3. Rest of Latin America
      • 9.4.3.1. By Drug Class

10. Middle East & Africa Atrial Fibrillation Market Analysis, Insights and Forecast, 2021-2034

  • 10.1. Market Analysis, Insights and Forecast - By Drug Class
    • 10.1.1. Anticoagulants
    • 10.1.2. Anti-arrhythmic Drugs
  • 10.2. Market Analysis, Insights and Forecast - By Route of Administration
    • 10.2.1. Oral
    • 10.2.2. Intravenous
    • 10.2.3. Others
  • 10.3. Market Analysis, Insights and Forecast - By Distribution Channel
    • 10.3.1. Hospital Pharmacies
    • 10.3.2. Online Pharmacies
    • 10.3.3. Retail Pharmacies
  • 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-region
    • 10.4.1. GCC
      • 10.4.1.1. By Drug Class
    • 10.4.2. South Africa
      • 10.4.2.1. By Drug Class
    • 10.4.3. Rest of Middle East & Africa
      • 10.4.3.1. By Drug Class

11. Competitive Analysis

  • 11.1. Global Market Share Analysis (2025)
  • 11.2. Company Profiles
    • 11.2.1. Bristol-Myers Squibb Company
      • 11.2.1.1. Overview
      • 11.2.1.2. Product
      • 11.2.1.3. SWOT Analysis
      • 11.2.1.4. Recent Developments
      • 11.2.1.5. Strategies
      • 11.2.1.6. financials (Based on Availability)
    • 11.2.2. Sanofi
      • 11.2.2.1. Overview
      • 11.2.2.2. Product
      • 11.2.2.3. SWOT Analysis
      • 11.2.2.4. Recent Developments
      • 11.2.2.5. Strategies
      • 11.2.2.6. financials (Based on Availability)
    • 11.2.3. Eisai Co., Ltd.
      • 11.2.3.1. Overview
      • 11.2.3.2. Product
      • 11.2.3.3. SWOT Analysis
      • 11.2.3.4. Recent Developments
      • 11.2.3.5. Strategies
      • 11.2.3.6. financials (Based on Availability)
    • 11.2.4. Johnson & Johnson
      • 11.2.4.1. Overview
      • 11.2.4.2. Product
      • 11.2.4.3. SWOT Analysis
      • 11.2.4.4. Recent Developments
      • 11.2.4.5. Strategies
      • 11.2.4.6. financials (Based on Availability)
    • 11.2.5. Daiichi Sankyo, Inc.
      • 11.2.5.1. Overview
      • 11.2.5.2. Product
      • 11.2.5.3. SWOT Analysis
      • 11.2.5.4. Recent Developments
      • 11.2.5.5. Strategies
      • 11.2.5.6. financials (Based on Availability)
    • 11.2.6. Par Pharmaceutical
      • 11.2.6.1. Overview
      • 11.2.6.2. Product
      • 11.2.6.3. SWOT Analysis
      • 11.2.6.4. Recent Developments
      • 11.2.6.5. Strategies
      • 11.2.6.6. financials (Based on Availability)
    • 11.2.7. Bayer AG
      • 11.2.7.1. Overview
      • 11.2.7.2. Product
      • 11.2.7.3. SWOT Analysis
      • 11.2.7.4. Recent Developments
      • 11.2.7.5. Strategies
      • 11.2.7.6. financials (Based on Availability)
    • 11.2.8. Pfizer Inc.
      • 11.2.8.1. Overview
      • 11.2.8.2. Product
      • 11.2.8.3. SWOT Analysis
      • 11.2.8.4. Recent Developments
      • 11.2.8.5. Strategies
      • 11.2.8.6. financials (Based on Availability)

List of Tables

  • Table 1: Global Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 2: Global Atrial Fibrillation Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 3: Global Atrial Fibrillation Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 4: Global Atrial Fibrillation Market Revenue (USD billion) Forecast, by Region, 2021-2034
  • Table 5: North America Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 6: North America Atrial Fibrillation Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 7: North America Atrial Fibrillation Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 8: North America Atrial Fibrillation Market Revenue (USD billion) Forecast, By Country, 2021-2034
  • Table 9: U.S. Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 10: Canada Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 11: Europe Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 12: Europe Atrial Fibrillation Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 13: Europe Atrial Fibrillation Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 14: Europe Atrial Fibrillation Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 15: Germany Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 16: U.K. Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 17: France Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 18: Italy Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 19: Spain Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 20: Scandinavia Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 21: Rest of Europe Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 22: Asia Pacific Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 23: Asia Pacific Atrial Fibrillation Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 24: Asia Pacific Atrial Fibrillation Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 25: Asia Pacific Atrial Fibrillation Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 26: Japan Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 27: India Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 28: China Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 29: Australia Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 30: Southeast Asia Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 31: Rest of Asia Pacific Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 32: Latin America Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 33: Latin America Atrial Fibrillation Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 34: Latin America Atrial Fibrillation Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 35: Latin America Atrial Fibrillation Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 36: Brazil Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 37: Mexico Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 38: Rest of Latin America Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 39: Middle East & Africa Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 40: Middle East & Africa Atrial Fibrillation Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
  • Table 41: Middle East & Africa Atrial Fibrillation Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
  • Table 42: Middle East & Africa Atrial Fibrillation Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
  • Table 43: GCC Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 44: South Africa Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034
  • Table 45: Rest of Middle East & Africa Atrial Fibrillation Market Revenue (USD billion) Forecast, by Drug Class, 2021-2034

List of Figures

  • Figure 1: Global Atrial Fibrillation Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
  • Figure 2: Global Atrial Fibrillation Market Value Share (%), by Drug Class, 2025 & 2034
  • Figure 3: Global Atrial Fibrillation Market Value Share (%), by Route of Administration, 2025 & 2034
  • Figure 4: Global Atrial Fibrillation Market Value Share (%), by Distribution Channel, 2025 & 2034
  • Figure 5: Global Atrial Fibrillation Market Value Share (%), by Region, 2025 & 2034
  • Figure 6: North America Atrial Fibrillation Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 7: North America Atrial Fibrillation Market Value Share (%), by Drug Class, 2025
  • Figure 8: North America Atrial Fibrillation Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 9: North America Atrial Fibrillation Market Value Share (%), by Route of Administration, 2025
  • Figure 10: North America Atrial Fibrillation Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 11: North America Atrial Fibrillation Market Value Share (%), by Distribution Channel, 2025
  • Figure 12: North America Atrial Fibrillation Market Value (USD billion), By Country, 2025 & 2034
  • Figure 13: North America Atrial Fibrillation Market Value Share (%), By Country, 2025
  • Figure 14: Europe Atrial Fibrillation Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 15: Europe Atrial Fibrillation Market Value Share (%), by Drug Class, 2025
  • Figure 16: Europe Atrial Fibrillation Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 17: Europe Atrial Fibrillation Market Value Share (%), by Route of Administration, 2025
  • Figure 18: Europe Atrial Fibrillation Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 19: Europe Atrial Fibrillation Market Value Share (%), by Distribution Channel, 2025
  • Figure 20: Europe Atrial Fibrillation Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 21: Europe Atrial Fibrillation Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 22: Asia Pacific Atrial Fibrillation Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 23: Asia Pacific Atrial Fibrillation Market Value Share (%), by Drug Class y, 2025
  • Figure 24: Asia Pacific Atrial Fibrillation Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 25: Asia Pacific Atrial Fibrillation Market Value Share (%), by Route of Administration, 2025
  • Figure 26: Asia Pacific Atrial Fibrillation Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 27: Asia Pacific Atrial Fibrillation Market Value Share (%), by Distribution Channel, 2025
  • Figure 28: Asia Pacific Atrial Fibrillation Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 29: Asia Pacific Atrial Fibrillation Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 30: Latin America Atrial Fibrillation Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 31: Latin America Atrial Fibrillation Market Value Share (%), by Drug Class, 2025
  • Figure 32: Latin America Atrial Fibrillation Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 33: Latin America Atrial Fibrillation Market Value Share (%), by Route of Administration, 2025
  • Figure 34: Latin America Atrial Fibrillation Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 35: Latin America Atrial Fibrillation Market Value Share (%), by Distribution Channel, 2025
  • Figure 36: Latin America Atrial Fibrillation Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 37: Latin America Atrial Fibrillation Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 38: Middle East & Africa Atrial Fibrillation Market Value (USD billion), by Drug Class, 2025 & 2034
  • Figure 39: Middle East & Africa Atrial Fibrillation Market Value Share (%), by Drug Class, 2025
  • Figure 40: Middle East & Africa Atrial Fibrillation Market Value (USD billion), by Route of Administration, 2025 & 2034
  • Figure 41: Middle East & Africa Atrial Fibrillation Market Value Share (%), by Route of Administration, 2025
  • Figure 42: Middle East & Africa Atrial Fibrillation Market Value (USD billion), by Distribution Channel, 2025 & 2034
  • Figure 43: Middle East & Africa Atrial Fibrillation Market Value Share (%), by Distribution Channel, 2025
  • Figure 44: Middle East & Africa Atrial Fibrillation Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
  • Figure 45: Middle East & Africa Atrial Fibrillation Market Value Share (%), By Country/ Sub-region, 2025
  • Figure 46: Global Atrial Fibrillation Market Share (%), By Company, 2025